Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook
Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
Glaukos Announces First Quarter 2026 Financial Results
Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy
Glaukos Announces the Release of its 2025 Sustainability Report
Glaukos Receives Permanent J-code for Epioxa™
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Capricorn Fund Managers Ltd Invests $6.78 Million in Glaukos Corporation $GKOS
Reviewing Anteris Technologies Global (NASDAQ:AVR) and Glaukos (NYSE:GKOS)
Glaukos Corporation $GKOS Shares Acquired by Allspring Global Investments Holdings LLC
Glaukos (NYSE:GKOS) CFO Sells $267,321.06 in Stock
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments
Glaukos Corporation (NYSE:GKOS) Given Average Rating of “Moderate Buy” by Brokerages
Why Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report?
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care
Capital International Investors Buys 264,971 Shares of Glaukos Corporation $GKOS
Citigroup Inc. Sells 34,689 Shares of Glaukos Corporation $GKOS
Glaukos (NYSE:GKOS) Director Aimee Weisner Sells 15,000 Shares
Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook
These Analysts Boost Their Forecasts On Glaukos Following Q4 Results
Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript
Glaukos (GKOS) Reports Q4 Earnings: What Key Metrics Have to Say
Glaukos (GKOS) Reports Q4 Loss, Beats Revenue Estimates
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
Comparing Glaukos (NYSE:GKOS) & Inogen (NASDAQ:INGN)
Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy?
Principal Financial Group Inc. Reduces Stock Position in Glaukos Corporation $GKOS
Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards
Director Sells GKOS 15,000 Shares for $1.9 Million
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Glaukos (NYSE:GKOS) Stock Price Up 6% Following Analyst Upgrade
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
Glaukos Corporation (NYSE:GKOS) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Glaukos Corporation $GKOS Shares Sold by Texas Permanent School Fund Corp
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Ameritas Investment Partners Inc. Has $590,000 Holdings in Glaukos Corporation $GKOS
Here's Why You Should Retain Glaukos Stock in Your Portfolio
Glaukos (GKOS) Up 20% Since Last Earnings Report: Can It Continue?